Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asterasys CoXKRX:450950 -4.29%23 EBITDA Margin % is 8.90% as of Jun. 2026, which is 70% below its 10-year median of 29.21. GuruFocus rates XKRX:450950 with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Asterasys Co ranks better than 76.44% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Asterasys Co's EBITDA for the
three
months ended in Jun. 2026 was ₩999 Mil. Asterasys Co's Revenue for the
three
months ended in Jun. 2026 was ₩11,222 Mil. Therefore, Asterasys Co's EBITDA margin for the quarter that ended in Jun. 2026 was 8.90%.
Asterasys Co (XKRX:450950) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Asterasys Co EBITDA Margin % Related Terms
Asterasys Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Asterasys Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:450950 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Asterasys Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asterasys Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Asterasys Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Asterasys Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asterasys Co (XKRX:450950) has a EBITDA Margin % of 8.90% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asterasys Co and its competitors. This is 70% below median its historical median of 29.21. Over the past decade, Asterasys Co's EBITDA Margin % has ranged from 17.00 to 33.33. According to the industry distribution chart, Asterasys Co ranks #192 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 23.6%.
Is Asterasys Co's EBITDA Margin % too high?
Asterasys Co's current EBITDA Margin % of 8.90% is 70% below median its 10-year median of 29.21. Over the past 10 years, this metric has ranged from a low of 17.00 to a high of 33.33. The Medical Devices & Instruments industry median EBITDA Margin % is 7.90. Asterasys Co's value of 8.90% is 12.7% above this industry median. Based on the distribution chart, Asterasys Co ranks #192 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Asterasys Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Asterasys Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Asterasys Co ranks #192 out of 815 companies for EBITDA Margin %. This places Asterasys Co in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.90. Asterasys Co's value of 8.90% is 12.7% above this benchmark. Historically, Asterasys Co's own EBITDA Margin % has ranged from 17.00 to 33.33 over the past decade. While the company's 10-year median is 29.21 vs. the industry median of 7.90, Asterasys Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.90, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asterasys Co's current EBITDA Margin % of 8.90% is 12.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asterasys Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asterasys Co's current EBITDA Margin % is 8.90%, which is 70% below median its own 10-year median of 29.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asterasys Co stock overvalued right now?
Asterasys Co (XKRX:450950) has a current EBITDA Margin % of 8.90%. The current EBITDA Margin % is 8.90%, which is 70% below median its 10-year median of 29.21 and 12.7% above the Medical Devices & Instruments industry median of 7.90. Asterasys Co's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Asterasys Co (XKRX:450950), the current EBITDA Margin % is 8.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asterasys Co Ltd is a professional healthcare and biomedical corporation based in Korea. It is engaged in the Manufacture of electro-diagnostic and electro-therapeutic apparatuses featuring body composition analyzers such as the InBalance series and HIFU systems such as the Liftera series, it provides total solutions with healthcare, skincare, and IoT-oriented services that can connect with its product portfolio.
23GF Score
Get the complete analysis for XKRX:450950
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:450950 has been successfully added to your 
